Morningstar

Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium

Blue Lake Biotechnology is developing BLB201 as an intranasal vaccine to prevent acute and severe disease associated with RSV infection. Phase 1 clinical trial results demonstrate BLB201's safety and ...
Business Wire

Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...
Business Wire

Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...
Morningstar

Blue Lake Biotechnology to Resume Enrollment of RSV-negative Toddlers in Phase 1/2a Clinical Trial of BLB201

FDA clarifies path forward for ongoing development of Blue Lake’s industry-leading pediatric RSV vaccine Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing ...
Nature

Blue Lake Biotechnology, Inc., United States of America (USA)

The positions in the table below reflect the Blue Lake Biotechnology, Inc.'s position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links ...